|
|
||||||||
14J
18 Natural T Cell Number and Function in Autoimmune-Prone Mice1


* Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232;
Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, PA 17033; and
Department of Pathology, University of Florida, Gainesville, FL 32610
| Abstract |
|---|
|
|
|---|
14J
18 TCR
-chain-positive natural T (iNKT) cells that do not release IL-4 in response to in vivo activation through their Ag receptor. The deficit in iNKT cell number and function is implicated in immune dysregulation and the etiology of TID. Therefore, we reasoned that the genetic determinant(s) that controls iNKT cell number and function might lie within Idd (insulin-dependent diabetes susceptibility locus) regions, which are known to contain TID resistance or susceptibility genes. A systematic analysis of iNKT cell number and function in Idd congenic mice revealed that neither iNKT cell number nor their inability to rapidly secrete IL-4 in response to acute in vivo activation by Ag underlies the mechanism of protection from diabetes in Idd congenic mice. Moreover, the regulation of iNKT cell number and function appears to be under the control of several genes. The most notable of these map to the Idd4, Idd5, Idd9.1, and Idd13 regions of the mouse genome. Together these findings provide a clue to the genetic mechanism(s) underlying iNKT cell deficiency in NOD mice. | Introduction |
|---|
|
|
|---|
cells of the islets of Langerhans. This human disease is best represented in nonobese diabetic (NOD) mice. NODs genome predisposes the females of this strain to spontaneous development of TID. Introgression of co-isogenic chromosomal segments from resistant strains into NOD or vice versa has led to the identification of
20 diabetogenic (Idd) loci, revealing the polygenic nature of the disease (see reviews in Ref. 1). Of the numerous Idd loci, Idd1 is the best understood. It localizes to the H2g7 region, the MHC of NOD mice (2, 3, 4, 5, 6). Pathogenic H2g7-restricted CD4+ and CD8+ T lymphocytes are thought to be kept under check by immune regulatory cells such as the invariant V
14J
18 TCR
-chain-positive natural T (iNKT) cells (7, 8, 9) either directly or through the mediation of other cell types (e.g., dendritic cells (10) or CD4+DX5+ T lymphocytes (11).
NKT cells are a unique subset of T lymphocytes (12, 13, 14, 15, 16), the majority of which express an invariant V
14J
18
-chain preferentially paired with a V
8.2
-chain (13, 17, 18). The CD1d1 tetramer containing a synthetic glycolipid Ag
-galactosylceramide (19) specifically identifies the iNKT cells and hence serves as a powerful tool for tracking this T cell subset (20, 21, 22). The physiological role of iNKT cells, albeit elusive, is thought to be immunoregulatory in nature. Remarkably, in vivo stimulation of iNKT cells through their Ag receptor results in rapid and robust secretion of IL-4 and a spectrum of cytokines characteristic of Th1 and Th2 responses (reviewed in Ref. 23).
Consistent with its predicted role in vivo, autoimmune disease-prone mice have very few iNKT cells (24, 25, 26, 27, 28). Thus, NOD mice have less than half the number of iNKT cells compared with C57BL/6 or BALB/c mice (24, 25, 26). NOD iNKT cells secrete little, if any, IL-4 upon in vivo activation (24, 25). This deficiency is complemented in an IL-4- and IL-10-dependent manner by adoptive transfer of CD4-8- thymocytes, which includes iNKT cells, making the young NOD recipients TID resistant (29). Further, increasing the number of endogenous iNKT cells through V
14J
18 TCR transgenesis increases IL-4 production by NOD transgenics and protects them from TID (30). Moreover, the absence of NKT cells in NOD.129-CD1d0/0 mice increased TID incidence (9, 31) even in males, which ordinarily have delayed onset and relatively lower disease incidence compared with female NOD mice (9). Together these findings underscore the role of iNKT cells in down-regulating autoimmune responses in vivo.
Administration of
-galactosylceramide (
-GalCer), a synthetic CD1d-restricted iNKT cell Ag (19), into prediabetic NOD mice protects them from spontaneous and cyclophosphamide-induced TID (7, 8, 9). This protection appears to require IL-4, which elicits a Th2 response in treated animals (7, 32). Alternatively, IL-4 and CSF-2 elicited by iNKT cells can induce dendritic cell differentiation that promotes Th2-type CD4 responses (10), or iNKT cells can induce tolerance within diabetogenic T lymphocytes (33). Thus, the low numbers of iNKT cells in NOD mice and, consequently, the poor IL-4 response to activation are thought to be TID susceptibility factors in this mouse model.
Humans afflicted with TID have low numbers of V
24J
18 NKT cells (34), a homologue of mouse V
14J
18 T lymphocytes (14, 35, 36, 37, 38). V
14J
18 NKT cell clones derived from TID individuals elicit IFN-
, but not IL-4, upon activation (34). However, V
24J
18 NKT cell numbers vary tremendously in both nondiabetics (39, 40) and individuals with TID (39). Further, the robustness of the cytokine response correlated with NKT cell number (39). Thus, the protective role of NKT cells in TID appears controversial.
We hypothesized that normal numbers of functional iNKT cells develop in TID-resistant NOD.B10-Idd and B6.NOD-Idd congenics. Thus, using CD1d1-
GalCer tetramers and
GalCer, we tracked iNKT cells and probed their in vivo function in NOD mice. Our data indicate that neither iNKT cell number nor their inability to rapidly secrete IL-4 in response to in vivo activation by Ag underlies the mechanism of protection from TID. Moreover, the regulation of iNKT cell number and function appears to be under the control of genes that map to the Idd4, Idd5, Idd9.1, and Idd13 regions in mice.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6 (B6), NOD, and NOD.B10-Idd congenics, NOD.B10-Idd3, NOD.B10-Idd5, NOD.B10-Idd9 (R28), NOD.B10-Idd9.2 (R11), NOD.B10-Idd9.3 (R35), and NOD.B10-Idd10,18, were purchased from TaconicFarms (Germantown, NY). NOR/LtJ, B6.NOD.Idd/LtJ (B6.NOD-Idd3, 10, B6.NOD-Idd4, B6.NOD-Idd6, B6.NOD-Idd13) and NOD.NOR-Idd13 congenics were obtained from The Jackson Laboratory (Bar Harbor, ME), whereas NZM2410 and B6.NZM2410-Sle1 were obtained from the University of Florida (Gainesville, FL). B6.129-CD1d10/0 mice have been described previously (41); B6.129-CSF-20/0 mice (42) were a gift from Drs. M. Marino and L. J. Old (three backcross generations to C57BL/6). All mice were bred and maintained at Vanderbilt University Animal Care Division in compliance with Vanderbilt Universitys Institutional Animal Care and Use Committee regulations.
Abs and reagents
Abs and reagents for ELISA, cell surface, and intracellular staining were purchased from BD PharMingen (San Diego, CA) unless stated otherwise.
Generation of CD1d-glycolipid tetramers
The preparation of CD1d1-glycolipid tetramer has been described previously (43). Staining with CD1d1-glycolipid tetramer was performed by incubating 1 million cells on ice for 45 min at a concentration of 10 µg/ml.
Measurement of ex vivo cytokine response
Each mouse was injected with 10 µg of
GalCer diluted in PBS from a 220 µg/ml stock solution in vehicle (0.5% (v/v) polysorbate-20 and 0.9% (w/v) NaCl) i.v. through the tail vein. Controls were injected with a corresponding dose of vehicle. Ninety minutes later, splenocytes from
GalCer- and vehicle-treated mice were harvested and immediately incubated in tissue culture for 2 h without restimulation with Ag. Supernatants were collected and used to measure IL-2, IL-4, CSF-2, IFN-
, and TNF-
by sandwich ELISA.
ELISA was performed using JES6-1A12, 11B11, R4-6A2 or MP1-22E9 capture Abs and biotinylated JES6-5H4, BVD6-24G2, XMG1.2, or MP1-31G6 Abs for measuring IL-2, IL-4, IFN-
, or CSF-2, respectively. TNF-
was detected with the DuoSet ELISA development system (R&D Systems, Minneapolis, MN). Pure recombinant cytokines were used to derive a standard curve for each cytokine from which the cytokine response was calculated.
Flow cytometry
Thymocytes of individual, age-matched (6- to 10-wk old) mice were stained for four-color flow cytometric analyses with anti-V
8.1,8.2-FITC (MR52), anti-CD161 (NKR-P1 or NK1.1)-FITC (PK136), anti-CD24 (heat-stable Ag (HSA))-PE (M1/69), anti-CD8a-PE (53-6.7), anti-TCR
-PE (H57-597), anti-CD8a-PerCP, and CD1d1-
GalCer-allophycocyanin tetramer. HSAlowCD8low or HSAlow thymocytes were electronically gated, and iNKT cells were analyzed. Splenocytes and hepatic mononuclear cells were stained with anti-V
8.1,8.2-FITC, anti-CD161-FITC, anti-CD45R/B220-PE (RA3-6B2), anti-TCR
-PE, anti-CD45R/B220-PerCP, and CD1d1-
GalCer tetramer after blocking with anti-CD16/CD32 (Fc
III/IIR) (2.4G2). CD45R/B220low cells were electronically gated, and iNKT cells were analyzed. Flow cytometry was performed with FACSCalibur, and the data were analyzed with CellQuest (BD Biosciences, SanJose, CA). Absolute iNKT cell number was calculated from the percentages of the CD1d tetramer-positive cells based on the total cell number obtained from each lymphoid organ (44).
Intracellular cytokine staining
Splenocytes from mice treated with
GalCer or vehicle control for 6 h in vivo were stained with anti-pan NK cell-FITC (DX5) and anti-CD3 molecular complex-CyChrome (17A2) after blocking with anti-CD16/CD32 (Fc
III/IIR; 2.4G2). These cells were then stained with anti-IFN-
-PE (XMG1.2) after fixing and permeabilizing with Cytofix/Cytoperm (BD Pharmingen) solution according to the manufacturers protocol. Flow cytometry was performed as described above.
| Results |
|---|
|
|
|---|
GalCer tetramers (henceforth, tetramers) were generated. Staining of C57BL/6-derived thymocytes, splenocytes (Fig. 1), and hepatic mononuclear cells (data not shown) revealed a distinct subset of lipid Ag-specific T lymphocytes of high frequency. Predictably, B6.129-CD1d10/0 and B6.129-TCR
0/0 thymus, spleen (Fig. 1), and liver (data not shown) had dramatically fewer, if any, iNKT cells. The
0.01% staining of B6.129-CD1d10/0 -derived leukocytes with tetramers was very similar to staining with
-mannosylceramide (
ManCer)-containing tetramer (Fig. 1). Note that
ManCer is not an iNKT cell Ag (19). Thus, the staining is considered background, and these data establish the specificity of the tetramer reagent.
|
Enumeration of iNKT cells in autoimmune-prone and -resistant mice.
Previous studies have demonstrated that several autoimmune-prone mice, including NOD, have decreased numbers of iNKT cells (24, 25, 26, 27, 28). Because of the availability of Idd and Sle congenic strains, NOD, NOR, NZM2410, and B6.NZM-Sle1 mice were analyzed for iNKT cell content and function. NOR is a diabetes-resistant relative of NOD generated from a cross between NOD and C57BLKS mice (45). It carries
87% of the NOD genome, including the dominant Idd1 region. The remaining
13% of the NOR genome is contributed by C57BLKS (Fig. 2) (46). Because the low number of iNKT cells in NOD is thought to be an important factor in the development of TID, tetramers were used to enumerate this subset in C57BL/6, NOD, and NOR mice. As expected, iNKT cell number in NOD thymus, spleen, and liver was about one-third to one-half that in C57BL/6 lymphoid organs (Fig. 3, A and B). Surprisingly, however, thymic, splenic, and hepatic iNKT cell numbers in NOR were similar to those in NOD; NOR mice had about one-third to one-half the NKT cell content of C57BL/6 mice (Fig. 3, A and B). In contrast to NOD and NOR, lupus-prone NZM2410 and B6.NZM-Sle1 mice, a congenic strain carrying a disease-susceptible region, have very high numbers of hepatic iNKT cells compared with C57BL/6 animals (Fig. 3, C and D). In fact, the absolute hepatic NKT cell number in NZM2410 was 5-fold higher than that of C57BL/6 mice (Fig. 3D). Thus, resistance to autoimmunity does not correlate with iNKT cell number.
|
|
GalCer-induced response of iNKT cells in disease-resistant NOR was studied along with C57BL/6 as a positive and NOD as a negative control. Ninety minutes after a single i.v. injection of
GalCer, IL-2 as well as both proinflammatory cytokine (IFN-
, CSF-2, and TNF-
) and IL-4 responses were monitored in tissue culture supernatants following in vitro culture for 2 h. To analyze the results quantitatively, the amount of cytokine secreted was plotted against the splenic iNKT cell numbers shown in Fig. 3B. A diagonal was set from zero at the abscissa and the ordinate to the level of cytokine production in activated C57BL/6 splenocytes. The values above and below the diagonal indicate average cytokine response less or greater than, respectively, that of the C57BL/6 positive control on a per cell basis.
As expected, C57BL/6 splenocytes elicited robust proinflammatory cytokine and IL-4 responses within 2 h of culture in vitro (Fig. 3E). Under similar conditions, NOD and NOR elicited little, if any, IL-2 and IL-4 (Fig. 3E). However, unlike NOD, IFN-
and CSF-2 responses were lower in NOR (Fig. 3E). TNF-
responses were near equal on a per cell basis in all three strains of mice (Fig. 3E). Interestingly, consistent with their high numbers, iNKT cells elicited higher amounts of cytokines in NZM2410 and B6.NZM-Sle1 compared with C57BL/6 mice (Fig. 3F). Thus, both TID-resistant NOR and TID-susceptible NOD mice are defective in eliciting acute IL-2 and IL-4 responses to
GalCer stimulation in vivo. Further, it is apparent that the genetic background of the mouse studied strongly influences iNKT cell number and function.
trans-Activation of NK cells by
GalCer-stimulated NKT cells is intact in NOR mice.
In vivo Ag-activated iNKT cells can trans-activate NK cells to secrete IFN-
(47). To determine the status of the trans-activation function of iNKT cells in NOD and NOR, we injected mice with
GalCer or vehicle control and monitored intracellular IFN-
within splenic NK cells 6 h later. Stimulation of iNKT cells in vivo with
GalCer resulted in an IFN-
response in NK cells (Fig. 3G). This response of NK cells was absent in B6.129-CD1d10/0 mice (data not shown), which develop NK cells, but not NKT cells (48). Of further note, CD3+ DX5+ and CD3+ DX5- cells produced very little, if any, IFN-
during the 6 h of
GalCer stimulation in vivo (data not shown). Interestingly, however, the IFN-
response of NK cells did not correlate with iNKT cell number, because NOR mice, which have about the same number of NKT cells as NOD mice, activated similar numbers of NK cells as C57BL/6 (Fig. 3G). Thus, the trans-activation function of iNKT cells was restored in NOR mice.
Introgression of C57BL/10s Idd9 region into NOD increases iNKT cell number, but does not rescue function
Enumeration of iNKT cells in Idd9 congenic and subcongenic mice.
NOR contains Idd4, Idd5, Idd9/11, and Idd13 from C57BLKS (Fig. 2) (46). Because each Idd region contains numerous genes, the ability of in vivo activated iNKT cells to trans-activate NK cells could be the result of both positive and negative influences imparted by products of genes within Idd4, Idd5, Idd9/11, and/or Idd13. Therefore, we systematically determined iNKT cell numbers in the available NOD.B10-Idd congenics, which included NOD.B10-Idd3, NOD.B10-Idd5, NOD.B10-Idd9, and NOD.B10-Idd10,18. These congenics have individual Idd regions introgressed from the resistant strain into NOD mice. The data revealed that NOD.B10-Idd9, but not NOD.B10-Idd3, NOD.B10-Idd5, and NOD.B10-Idd10,18, had slightly increased numbers of iNKT cells that reacted with the tetramers compared with those in NOD mice (Fig. 4, AD). NOD.B10-Idd9 thymus and spleen had iNKT cells that constitute
6070% of those in C57BL/6 (Fig. 4, C and D). Additionally, thymic and splenic iNKT cell numbers in NOD.B10-Idd9 were 5070% greater than those in NOD mice (Fig. 4, C and D). In contrast, hepatic NKT cell numbers in NOD and NOD congenics were almost the same and were about one-fourth of that found in C57BL/6 mice (Fig. 4, AD).
|
iNKT cells of Idd9 congenic and subcongenic mice respond poorly to
GalCer stimulation.
The finding that NOD.B10-Idd9 animals have slightly higher numbers of iNKT cells raised the question of whether the functions attributed to this T lymphocyte subset were restored. Thus, we determined the acute cytokine response of iNKT cells as described above. C57BL/6 splenocytes elicited a robust proinflammatory cytokine IL-4 responses within 2 h of culture in vitro following in vivo activation by Ag. Under similar conditions, NOD and NOD congenics elicited little IL-4 (Fig. 4E and data not shown). However, akin to the positive control, mice of NOD background secreted equal (NOD, R28, and R11) or greater (R35) amounts of IFN-
and CSF-2 (Fig. 4E). The IL-2 response of NOD background mice was clearly lower than that of C57BL/6 splenocytes, but their TNF-
responses were nearly equal (Fig. 4E). Thus, although the introgression of Idd9 into NOD mice partially restores thymic and splenic iNKT cell number, their acute cytokine response reflects that of the NOD strain background.
To determine the roles of genes within the Idd9 region in trans-activation of NK cells by
GalCer-stimulated NKT cells, we monitored intracellular IFN-
within splenic NK cells 6 h after i.v. injection of
GalCer or vehicle control. The data revealed that the IFN-
response in NK cells was restored, close to the levels observed in C57BL/6 mice, in R28, which carries the entire Idd9 region, but not in R35 (Idd9.2 and Idd9.3) or R11 (Idd9.3; Fig. 4F). Thus, at least one of the genes that control the trans-activation function of iNKT cells maps to the Idd9.1 subregion.
Introgression of individual NOD-derived Idd into C57BL/6 decreases iNKT cell number and alters their function
One reason for the lack of association between TID and iNKT cell number and function in the preceding analyses could be due to the influence of multiple dominantly acting negative factors dispersed in the NOD background. In the NOD.B10-Idd congenics, the negative factors may not be overcome by the introgression of an individual Idd region from the resistant strain. Therefore, we reasoned that the introgression of a dominantly acting negative gene(s) into a genetic background that generates normal numbers of functional V
14J
18 T cells (e.g., C57BL/6) would result in reduced numbers and/or functionally deficient iNKT cells. To test this possibility, the absolute number and function of iNKT cells were systematically analyzed in B6.NOD-Idd congenics as described in the preceding sections.
B6.NOD-Idd3,10, B6.NOD-Idd6, and B6.NOD-Idd13 mice contain near normal numbers of thymic, splenic, and hepatic iNKT cells (Fig. 5, A and B). Further, consistent with the presence of near normal number of V
14J
18 T cells, only B6.NOD-Idd6 NKT cells elicited a robust IL-4 response to
GalCer stimulation in vivo like that of the control C57BL/6 animals (Fig. 5C). Surprisingly, unlike the control C57BL/6 animals, B6.NOD-Idd6 mice did not elicit an IFN-
response to in vivo challenge with the Ag (Fig. 5C). Thus, contrary to what might have been predicted based upon a previous report (50), but consistent with the conclusion of another study (26), we find that NOD alleles within the Idd6 region failed to regulate iNKT cell number and function when introgressed into the C57BL/6 strain background.
|
GalCer. The two strains showed pronounced defects in acute IL-2, IL-4, IFN-
, and CSF-2 responses to in vivo activation with
GalCer (Fig. 5C). Strikingly, however, B6.NOD-Idd4, congenic mice have reduced numbers of hepatic iNKT cells despite near normal iNKT cell content within thymus and spleen (Fig. 5, A and B). Consistent with the low hepatic iNKT cell number, the activation of Idd4-derived NKT cells in vivo by
GalCer resulted in a reduced cytokine response in this congenic strain (Fig. 5C).
We also observed that the activated iNKT cell-induced trans-activation of NK cells to elicit an IFN-
response was significantly affected in B6.NOD-Idd13 mice, which closely resembled NOD mice (Fig. 5D). This trans-activation function was lower in B6.NOD-Idd4 and B6.NOD-Idd5 animals, but resembled an intermediate between C57BL/6 and NOD (Fig. 5D). NK cell activation and the IFN-
response to
GalCer in B6.NOD-Idd3,10 and B6.NOD-Idd6 resembled those in C57BL/6 mice (Fig. 5D).
Together these data suggest that genes within Idd4 influence the maintenance and/or hepatic homing of iNKT cell number. Further, one or more genes localized within Idd3/10, Idd4, and Idd13 regions impart a negative effect on iNKT cell function in a mouse strain background-dependent fashion.
| Discussion |
|---|
|
|
|---|
24J
18 NKT cells in human autoimmune diabetes (39), iNKT cell deficiency and dysfunction alone cannot explain the NOD strains unique susceptibility to spontaneous development of TID. Moreover, we have identified regions within the mouse genome that control iNKT cell ontogeny and function.
|
Several genes of immunological import map within Idd3/10, Idd4, and Idd13 regions (see Fig. 2 and Table I). The currently available mapping data suggest that Idd13 of NOR is C57BLKS derived (46). Because iNKT cell number and function are not very different in NOD and NOR mice, the Idd13 region is less likely to contain genetic information for the development and function of this T cell subset. On the other hand, Idd4 and Idd3/10 regions of NOR are largely of NOD origin (Fig. 2) (46).
Previous reports have indicated that mice deficient in IL-2 (44), IL-7 (54), and IL-12a (53) do not alter NKT cell development. On the other hand, IFN regulatory factor-1-deficient (55), CD1d-deficient (41, 48, 56), and
2-microglobulin-deficient (13) mice do not develop NKT cells. Among the remaining genes that map to the Idd4 and Idd13 intervals on chromosomes 11 and 2, respectively, we focused on the putative Idd4 candidate CSF-2 because it was shown to induce the rearrangement and expression of V
14J
18 within a putative precursor NKT cell in vitro (57). Analysis of CSF-20/0 thymocytes, splenocytes, and hepatic mononuclear cells with the CD1d1-
GalCer tetramer revealed slightly, but not significantly, reduced iNKT cell number compared with that of lymphoid organs in wild-type littermates (N. Matsuki, A. K. Stanic, and S. Joyce, unpublished observations). Interestingly, the iNKT cells in CSF-20/0 mice responded poorly to in vivo
GalCer stimulation; they elicited very little IL-4 and only weakly trans-activated NK cells to secrete IFN-
. To determine whether the Idd4 phenotype described herein resulted from aberrant CSF-2 function in NOD mice, B6.NOD-Idd4 mice were crossed with CSF-2+/0 and CSF-20/0 animals. Both crosses rescued the low NKT cell content and poor IL-4 response to
GalCer observed in B6.NOD-Idd4. These data implicate a gene(s) outside the CSF-2 locus, e.g., ICAM-2 and/or CCR9, that may be responsible for the Idd4 phenotype.
A previous report has shown that the introgression of the C57BL/6 NK locus, which maps to Idd6 and a part of the flanking regions, into NOD conferred resistance to TID. Additionally, the NOD.B6-NK mice had increased iNKT cell numbers, which restored the IL-4-secreting and NK cell trans-activation functions of this T lymphocyte subset (50). Another study, however, reported contrasting results regarding NKT cell number and function in the NOD.B6-NK mice (26). Consistent with the latter report, B6.NOD-Idd6, which also encompasses the NK region, did not have lower iNKT cell number, nor were these T lymphocytes NOD-like in their function (summarized in Table I). The reason(s) for these contrasting results needs further investigation.
In conclusion, the data presented herein reveal that neither iNKT cell number nor their inability to rapidly secrete IL-4 in response to in vivo activation by Ag underlies the mechanism of protection from diabetes in NOR and Idd congenic mice. Moreover, the regulation of iNKT cell number and function appears to be under the control of several genes. The most notable of these map to the Idd4, Idd5, Idd9.1, and Idd13 regions of the mouse genome. A gene(s) within the Idd4 region, but outside the CSF-2 locus, controls iNKT cell number and function. Together these findings provide a clue to the genetic mechanism(s) underlying iNKT cell deficiency in NOD mice.
| Acknowledgments |
|---|
GalCer and
ManCer; Drs. M. Marino and L. J. Old for generous supplies of B6.129-CSF-20/0 mice; Dr. E. H. Leiter for the generous supply of NOD.NOR-Idd13 and B6.NOD-Idd/LtJ congenic mice; Drs. O. V. Naidenko and M. Kronenberg for helpful advice on putting together CD1d1-
-galactosylceramide tetramers; and Drs. D. C. Roopenian, D. V. Serreze, and L. Wicker for critical evaluation of the data and helpful discussions. We thank members of the Joyce Laboratory for critical evaluation of the data, comments on the manuscript, and support. | Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Sebastian Joyce, Department of Microbiology and Immunology, A4223 Medical Center North, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN 37232. E-mail address: sebastian.joyce{at}vanderbilt.edu ![]()
3 Abbreviations used in this paper: TID, type I diabetes;
GalCer,
-galactosylceramide; HSA, heat-stable Ag; Idd, insulin-dependent diabetes susceptibility locus;
ManCer,
-mannosylceramide; NOD, nonobese diabetic; iNKT, invariant V
14J
18 TCR
-chain-positive natural T. ![]()
Received for publication January 3, 2003. Accepted for publication March 24, 2003.
| References |
|---|
|
|
|---|
-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:1052.[Medline]
-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7:1057.[Medline]
8+ subset. J. Immunol. 145:1039.[Abstract]
24+ CD4-CD8- T cells. J. Exp. Med. 186:109.
TCR+ NK1.1+ cells. J. Immunol. 145:3209.[Abstract]
chain is used by a unique subset of MHC class I specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180:1097.
14 NKT cells by glycosylceramides. Science 278:1626.
TCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 46:572.[Abstract]
14+ NK T cells associated with disease development in autoimmune prone mice. J. Immunol. 156:4035.[Abstract]
/
-T cell receptor (TCR)+ CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in non-obese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047.
14Ja281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188:1831.
-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163:2373.
24JaQ T cells in type 1 diabetes. Nature 391:177.[Medline]
24J
Q/V
11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J. Exp. Med. 180:1171.
24 natural killer T cells. J. Exp. Med. 195:637.
24-JaQ TCR
are CD4- and heterogeneous with respect to TCR
expression. Hum. Immunol. 48:63.[Medline]
14J
18 NKT lymphocyte antigen caused by
-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 100:1849.
chain and interleukin 7 receptor
chain in natural T cell development. J. Exp. Med. 186:331.
+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187:967.
14 NKT cells by granulocyte/macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA 96:7439.This article has been cited by other articles:
![]() |
A. Ueno, J. Wang, L. Cheng, J. S. Im, Y. Shi, S. A. Porcelli, and Y. Yang Enhanced Early Expansion and Maturation of Semi-Invariant NK T Cells Inhibited Autoimmune Pathogenesis in Congenic Nonobese Diabetic Mice J. Immunol., November 15, 2008; 181(10): 6789 - 6796. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsukamoto, M. Ohtsuji, W. Shiroiwa, Q. Lin, K. Nakamura, H. Tsurui, Y. Jiang, K. Sudo, H. Nishimura, T. Shirai, et al. Aberrant Genetic Control of Invariant TCR-Bearing NKT Cell Function in New Zealand Mouse Strains: Possible Involvement in Systemic Lupus Erythematosus Pathogenesis J. Immunol., April 1, 2008; 180(7): 4530 - 4539. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Safadi, E. Zigmond, O. Pappo, Z. Shalev, and Y. Ilan Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution Int. Immunol., August 13, 2007; (2007) dxm069v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Loh, Y.-C. Cai, G. Bonventi, G. Lajoie, R. MacLeod, and J. E. Wither Dissociation of the Genetic Loci Leading to B1a and NKT Cell Expansions from Autoantibody Production and Renal Disease in B6 Mice with an Introgressed New Zealand Black Chromosome 4 Interval J. Immunol., February 1, 2007; 178(3): 1608 - 1617. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Rocha-Campos, R. Melki, R. Zhu, N. Deruytter, D. Damotte, M. Dy, A. Herbelin, and H.-J. Garchon Genetic and Functional Analysis of the Nkt1 Locus Using Congenic NOD Mice: Improved V{alpha}14-NKT Cell Performance but Failure to Protect Against Type 1 Diabetes. Diabetes, April 1, 2006; 55(4): 1163 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Brodnicki, A. L. Fletcher, D. G. Pellicci, S. P. Berzins, P. McClive, F. Quirk, K. E. Webster, H. S. Scott, R. L. Boyd, D. I. Godfrey, et al. Localization of Idd11 Is Not Associated With Thymus and NKT Cell Abnormalities in NOD Mice Diabetes, December 1, 2005; 54(12): 3453 - 3457. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Margalit, S. A. Ghazala, R. Alper, E. Elinav, A. Klein, V. Doviner, Y. Sherman, B. Thalenfeld, D. Engelhardt, E. Rabbani, et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G917 - G925. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Kent, Y. Chen, S. M. Clemmings, V. Viglietta, N. S. Kenyon, C. Ricordi, B. Hering, and D. A. Hafler Loss of IL-4 Secretion from Human Type 1a Diabetic Pancreatic Draining Lymph Node NKT Cells J. Immunol., October 1, 2005; 175(7): 4458 - 4464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Bezbradica, A. K. Stanic, N. Matsuki, H. Bour-Jordan, J. A. Bluestone, J. W. Thomas, D. Unutmaz, L. Van Kaer, and S. Joyce Distinct Roles of Dendritic Cells and B Cells in Va14Ja18 Natural T Cell Activation In Vivo J. Immunol., April 15, 2005; 174(8): 4696 - 4705. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rolf, V. Motta, N. Duarte, M. Lundholm, E. Berntman, M.-L. Bergman, L. Sorokin, S. L. Cardell, and D. Holmberg The Enlarged Population of Marginal Zone/CD1dhigh B Lymphocytes in Nonobese Diabetic Mice Maps to Diabetes Susceptibility Region Idd11 J. Immunol., April 15, 2005; 174(8): 4821 - 4827. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Bezbradica, T. Hill, A. K. Stanic, L. Van Kaer, and S. Joyce Commitment toward the natural T (iNKT) cell lineage occurs at the CD4+8+ stage of thymic ontogeny PNAS, April 5, 2005; 102(14): 5114 - 5119. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Stanic, J. S. Bezbradica, J.-J. Park, L. Van Kaer, M. R. Boothby, and S. Joyce Cutting Edge: The Ontogeny and Function of Va14Ja18 Natural T Lymphocytes Require Signal Processing by Protein Kinase C{theta} and NF-{kappa}B J. Immunol., April 15, 2004; 172(8): 4667 - 4671. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Stanic, J. S. Bezbradica, J.-J. Park, N. Matsuki, A. L. Mora, L. Van Kaer, M. R. Boothby, and S. Joyce NF-{kappa}B Controls Cell Fate Specification, Survival, and Molecular Differentiation of Immunoregulatory Natural T Lymphocytes J. Immunol., February 15, 2004; 172(4): 2265 - 2273. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Stanic, R. Shashidharamurthy, J. S. Bezbradica, N. Matsuki, Y. Yoshimura, S. Miyake, E. Y. Choi, T. D. Schell, L. Van Kaer, S. S. Tevethia, et al. Another View of T Cell Antigen Recognition: Cooperative Engagement of Glycolipid Antigens by Va14Ja18 Natural TCR J. Immunol., November 1, 2003; 171(9): 4539 - 4551. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |